Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 1167

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1
Chunk 1167
---
 because there is little legal precedent governing the interpretation of certain terms of common open-source licenses. In
addition, if Renovaro Cube or BioSymetrics combines its proprietary software with open-source software in a certain manner and
makes it available to others, under some open-source licenses, it could be required to license or make available the source
code of its proprietary software, which could substantially help its competitors develop products that are similar to or better than ours
and harm our business.

The
success and growth of Renovaro Cube’s or BioSymetrics’ business depends upon their ability to continuously innovate and develop
new products and technologies.

Renovaro
Cube’s and BioSymetrics’ solutions are technology-driven platforms that rely on innovation to remain competitive. The process
of developing new technologies and products is complex, and we have built and seek to further develop our own technology using the latest
in AI and machine learning, cloud-based technologies and other tools to differentiate our products and technologies. In addition,
our dedication to incorporating technological advancements into our AI platforms requires significant financial and personnel resources
and talent. Our development efforts with respect to these initiatives could distract management from current operations and could divert
capital and other resources from other growth initiatives important to our business. We operate in an industry experiencing rapid technological
change and frequent product introductions. We may not be able to make technological improvements as quickly as demanded by our customers,
or we may not be able to accurately predict the demand or growth of its technological investments, which could harm its ability to attract
customers and have a material and adverse effect on its business, results of operations, financial condition and future prospects. In
addition, we may not be able to effectively implement new technology-driven products and services as quickly as our competitors or be
successful in marketing these products and services to potential customers. If we are unable to successfully and timely innovate, we could
experience reputational damage and decreased demand for our AI platforms and other products and technologies and our growth, business,
results of operations, financial condition and future prospects could be materially and adversely affected.

Renovaro
Cube’s and BioSymetrics’ AI platform and other related products may become obsolete due to fast growing technological innovations
or the entry of competitors with more financial and brand power.

AI is a fast-growing industry
and Renovaro Cube and BioSymetrics must successfully adapt and manage technological advancements in AI and AI-related markets,
as well as effectively compete with the emergence of additional